Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Divarasib - Genentech

Next Previous
Drug Profile

Divarasib - Genentech

Alternative Names: GDC-6036; RG 6330; RO-7435846

Latest Information Update: 22 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Aminopyridines; Antineoplastics; Chlorinated hydrocarbons; Fluorine compounds; Ketones; Piperazines; Pyrrolidines; Quinazolines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 22 Oct 2025 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in Taiwan, Hong Kong, USA (PO) (NCT06793215)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Belgium (PO)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Brazil (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top